Drugs · acquisition-cost intelligence
Timolol maleate
· ingredient timololBeta blocking agents· TIMOLOL MALEATE 6.8 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.60
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other timolol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Timolol Maleate | $0.75535 | −$0.84530 |
| timolol maleate | $0.79615 | −$0.80450 |
| COSOPT | $0.92983 | −$0.67080 |
| COSOPT PF | $1.08 | −$0.52100 |
| Brimonidine Tartrate/Timolol Maleate | $2.38 | +$0.78270 |
| Timoptic in Ocudose | $5.94 | +$4.34 |
| Timolol GFS | $13.33 | +$11.73 |
| TIMOLOL MALEATE | $13.33 | +$11.73 |
Medicare Part D coverage · CY2026
On 15 plan formularies · typical tier 4
Prior auth 7% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.